3DBio Therapeutics
- Industry
- Biotechnology
- Founded Year
- 2014
- Headquarters
- 51-36 35th Street, Long Island City, NY 11101, United States
- Employee Count
- 25
Key People
- Daniel Cohen - CEO and Co-Founder
- Lawrence Bonassar - Co-Founder
- Hod Lipson - Co-Founder
- Nathaniel Bachrach - Chief Scientific Officer and Executive Vice President
- Kevin Slawin - Director
- Lior Erez - Quality Assurance Manager
- Benjamin Cohen - Senior Scientist
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with backgrounds in biotechnology and regenerative medicine.
The presence of multiple successful MedTech entrepreneurs in the leadership team enhances the company's capability to navigate the complex landscape of biotechnology and regenerative medicine, fostering innovation and strategic growth.
- Clinical Need
-
Aspect: Very Strong
Summary: AuriNovo addresses a significant unmet need in reconstructive surgery for microtia patients.
Microtia is a congenital condition with limited effective treatment options. AuriNovo's innovative approach offers a personalized solution, potentially transforming the standard of care and significantly improving patient quality of life.
- Competition
-
Aspect: First mover
Summary: 3DBio Therapeutics is pioneering 3D-bioprinted living tissue implants for ear reconstruction.
As the first company to develop 3D-bioprinted living tissue implants for ear reconstruction, 3DBio Therapeutics has the opportunity to establish market leadership, set industry standards, and build strong brand recognition.
- Technical Challenge
-
Aspect: Very Complex
Summary: Developing bioprinted living tissues involves intricate biological and engineering challenges.
The process of creating functional, bioprinted living tissues requires precise control over cell behavior, material properties, and biocompatibility, presenting significant technical hurdles that could impact the speed and cost of product development.
- Patent
-
Aspect: Very Strong
Summary: The company holds proprietary technologies in 3D bioprinting and bio-inks.
Holding patents for key technologies such as the GMPrint bioprinter and ColVivo bio-ink provides 3DBio Therapeutics with a defensible market position, deterring competitors and potentially enabling lucrative licensing opportunities.
- Financing
-
Aspect: Medium
Summary: The company has secured funding from multiple investors but may require additional capital for commercialization.
While initial funding has supported development, the high costs associated with clinical trials, regulatory approval, and market entry may necessitate additional financing to achieve commercialization and scalability.
- Regulatory
-
Aspect: Pivotal Trial
Summary: AuriNovo has received Orphan Drug Designation and is progressing through clinical trials.
Although the Orphan Drug Designation facilitates certain regulatory advantages, the path to full approval involves rigorous clinical testing and compliance with FDA requirements, which can be time-consuming and carry inherent risks.
Opportunity Rollup
- Odds of Success
- 4
- Peak Market Share
- 5.65
- Segment CAGR
- 4.5%
- Market Segment
- ENT Devices
- Market Sub Segment
- Hearing Implants
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.28 |
| 2 | 0.85 |
| 3 | 1.98 |
| 4 | 3.95 |
| 5 | 5.65 |
Key Takeaway
3DBio Therapeutics is at the forefront of regenerative medicine with its innovative 3D-bioprinted ear implant, AuriNovo. While the company holds strong IP and addresses a significant clinical need, it faces technical complexities and financial challenges on its path to commercialization.